文献速递骨质疏松与代谢性骨病

炎症性肠病骨质疏松负担增加及抗骨吸收治疗比较的真实世界队列研究

Increased osteoporosis burden and comparative antiresorptive effectiveness in inflammatory bowel disease: a real-world cohort study.
PubMed 文献 · Osteoporos Int · 2026-04-17

该研究利用美国TriNetX网络构建两个回顾性队列,发现IBD患者5年内新发骨质疏松风险较非IBD对照高56%,克罗恩病风险最高;在IBD合并骨质疏松患者中,地舒单抗与双膦酸盐的1-2年骨折率相似。研究强调早期筛查、减少激素使用和个体化抗骨吸收治疗。

要点

  • IBD患者新发骨质疏松风险显著高于对照,克罗恩病风险最高。
  • 地舒单抗与双膦酸盐在IBD骨质疏松患者中1-2年骨折率相似。
  • 建议IBD患者早期进行骨健康筛查并个体化抗骨吸收治疗。

核心结论

  • IBD患者骨质疏松风险显著增高且为多因素,地舒单抗短期骨折率与双膦酸盐相似但差异不能排除。

研究设计与样本

  • 利用美国TriNetX网络构建两个回顾性队列:143,248例IBD成人按1:1倾向匹配非IBD对照;2,423例IBD合并骨质疏松患者(520例地舒单抗,1,903例双膦酸盐)匹配后比较骨折率。

主要发现

  • IBD患者1年新发骨质疏松风险较对照高58%(aOR 1.58,95%CI 1.51-1.65),克罗恩病aOR 1.79(95%CI 1.68-1.90),溃疡性结肠炎aOR 1.47(95%CI 1.39-1.56)。
  • 亚组分析显示溃疡性结肠炎中年龄>65岁、女性、亚洲种族风险增加;克罗恩病中年龄>65岁、女性、尼古丁依赖和饮酒与风险增加相关。
  • 地舒单抗与双膦酸盐1年骨折率2.33% vs 3.49%(aOR 0.65,95%CI 0.31-1.38),2年骨折率4.65% vs 6.78%(aOR 0.67,95%CI 0.39-1.14)。

关键数值与推荐

  • IBD患者1年新发骨质疏松aOR 1.58(95%CI 1.51-1.65),克罗恩病aOR 1.79(95%CI 1.68-1.90),溃疡性结肠炎aOR 1.47(95%CI 1.39-1.56)。
  • 地舒单抗 vs 双膦酸盐1年骨折aOR 0.65(95%CI 0.31-1.38),2年aOR 0.67(95%CI 0.39-1.14)。

临床怎么用

  • 对IBD患者应优先早期骨健康筛查,采用减少激素的策略,并根据个体情况选择抗骨吸收治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Contemporary IBD care lacks precise osteoporosis risk estimates and data on comparative therapy. In U.S., IBD patients had a 56% higher 5-year risk of a new osteoporosis diagnosis (highest in Crohn's disease); denosumab matched bisphosphonates for 1-2-year fracture prevention in this population. Our study prioritizes early screening, steroid-sparing strategies, and individualized antiresorptive therapy. BACKGROUND: Osteoporosis is a frequent extra-intestinal complication of inflammatory bowel disease (IBD), yet its current burden and the comparative efficacy of available anti-resorptive therapies remain uncertain. METHODS: Using the US TriNetX network we formed two retrospective cohorts. (1) Adults with IBD (2013-2023) were 1:1 propensity-matched to non-IBD controls to estimate 5-year risk of new osteoporosis diagnosis and identify determinants. (2) IBD patients with osteoporosis initiating denosumab or bisphosphonates (2013-2022) were matched for demographics, comorbidities, and IBD phenotype; spine/hip fractures and risk for incident onset fractures were calculated for both the cohorts. RESULTS: Among 143,248 patients with IBD (mean age 44.2 y; 51.8% female), risk of new osteoporosis diagnosis exceeded controls by 58% at 1 year (adjusted odds ratio [aOR] 1.58, 95% CI 1.51-1.65) and was highest in Crohn's disease (CD) (aOR 1.79, 95% CI 1.68-1.90); ulcerative colitis (UC) also demonstrated increased 1-year risk (aOR 1.47, 95% CI 1.39-1.56). Subgroup analysis showed increased risk in patients age > 65, female sex and Asian race for UC. For CD, age > 65, female sex, nicotine dependence and alcohol use were associated with increased risk. The osteoporosis treatment cohort included 2,423 patients (520 denosumab and 1,903 bisphosphonates). After matching, denosumab produced similar 1-year (2.33% vs 3.49%, aOR 0.65 CI 0.31-1.38) and 2-year (4.65% vs 6.78%; aOR 0.67, CI: 0.39-1.14) fracture rates compared to bisphosphonates. CONCLUSION: IBD confers a substantially higher and multifactorial osteoporosis risk. Denosumab showed similar observed short-term fracture rates to bisphosphonates, although clinically meaningful differences could not be excluded. Early bone-health screening, steroid-sparing therapy, and individualized antiresorptive treatment remain essential.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Desai A, Khataniar H, Habib H, et al. Increased osteoporosis burden and comparative antiresorptive effectiveness in inflammatory bowel disease: a real-world cohort study. Osteoporos Int. 2026. PMID: 41995805. doi:10.1007/s00198-026-08020-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。